trending Market Intelligence /marketintelligence/en/news-insights/trending/LD6DYU-QnWLRwOsOvAnMsw2 content esgSubNav
In This List

Fitch upgrades Bio-Rad's credit rating; outlook stable

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Fitch upgrades Bio-Rad's credit rating; outlook stable

Fitch Ratings has upgraded Bio-Rad Laboratories Inc.'s long-term issuer default ratings to BBB from BBB-.

The outlook on the ratings of the Hercules, Calif.-based company is stable, according to the rating agency.

The upgrade reflects Bio-Rad's improved EBITDA and free cash flow margins that have occurred due to the company's cost rationalization initiatives and improvement of internal controls. The company's leverage is strong for the current ratings and will allow headroom to pursue potentially expanded business development activity, Fitch said.

The ratings apply to $441 million of Bio-Rad's debt as of June 30, the rating agency noted.

Bio-Rad develops products for the life science research and clinical diagnostic markets.